Rbj的个人主页 - 老虎社区

Rbj

Rbj

暂无个人介绍

IP属地：未知

43关注

25粉丝

0主题

0勋章

2021-12-29

Interesting. Wherr will it go next

抱歉，原内容已删除

2021-12-28

Ok

抱歉，原内容已删除

2021-12-27

Coinbase pls break even

抱歉，原内容已删除

2021-12-25

Interesting. Not sure if I agree

抱歉，原内容已删除

2021-12-24

Good

How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?

2021-12-23

Hm

抱歉，原内容已删除

2021-12-21

Wow

抱歉，原内容已删除

2021-12-20

Go nio!

Will Nio's Newly-launched ET5 Pose A Threat To Tesla's Model 3?

2021-12-19

Please like ans comment

Wall Street ends down after mostly negative week

2021-12-18

Pls like and comment

Wall Street ends down after mostly negative week

2021-12-17

Sad.

抱歉，原内容已删除

2021-12-16

Good news?

抱歉，原内容已删除

2021-12-15

Nice!

Pfizer Says Its Covid-19 Pill Likely Works Against Omicron

2021-12-14

Sad

抱歉，原内容已删除

2021-12-13

Sigh

Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%

2021-12-11

Ok

抱歉，原内容已删除

2021-12-09

Good

抱歉，原内容已删除

2021-12-08

Wow

Pinduoduo shares surged 11% in morning trading

2021-12-07

Ok pls like

抱歉，原内容已删除

2021-12-06

Boom!

Former Netflix engineer and accomplice sentenced to prison for insider trading

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3575234837042918","uuid":"3575234837042918","gmtCreate":1612232198682,"gmtModify":1614062033214,"name":"Rbj","pinyin":"rbj","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":25,"headSize":43,"tweetSize":318,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-2","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资总监虎","description":"证券账户累计交易金额达到30万美元","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.99%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.46%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696535569,"gmtCreate":1640732959557,"gmtModify":1640732959844,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Interesting. Wherr will it go next","listText":"Interesting. Wherr will it go next","text":"Interesting. Wherr will it go next","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/696535569","repostId":"1186633322","repostType":4,"isVote":1,"tweetType":1,"viewCount":1159,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696199966,"gmtCreate":1640646444974,"gmtModify":1640646445294,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696199966","repostId":"1191134006","repostType":4,"isVote":1,"tweetType":1,"viewCount":852,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698761087,"gmtCreate":1640560211961,"gmtModify":1640560212323,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Coinbase pls break even","listText":"Coinbase pls break even","text":"Coinbase pls break even","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698761087","repostId":"2193178197","repostType":4,"isVote":1,"tweetType":1,"viewCount":2461,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698229143,"gmtCreate":1640412486371,"gmtModify":1640412486697,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Interesting. Not sure if I agree&nbsp;","listText":"Interesting. Not sure if I agree&nbsp;","text":"Interesting. Not sure if I agree","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698229143","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698330557,"gmtCreate":1640302282225,"gmtModify":1640302442076,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698330557","repostId":"1172289344","repostType":4,"repost":{"id":"1172289344","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640302012,"share":"https://www.laohu8.com/m/news/1172289344?lang=&edition=full","pubTime":"2021-12-24 07:26","market":"us","language":"en","title":"How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172289344","media":"Benzinga","summary":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for","content":"<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Much Revenue Could Pfizer's Oral COVID-19 Pill Fetch?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-24 07:26</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pfizer, Inc.</b>&nbsp;announced&nbsp;Wednesday its oral COVID-19 antiviral pill,&nbsp;<b>Paxlovid,</b>&nbsp;has been authorized for use by the U.S. Food and Drug Administration.</p>\n<p><b>The Pfizer Analysts:</b>SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.</p>\n<p>BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.</p>\n<p><b>Broad Label, Increased Supply To Give Pfizer Dominant Market Position:</b>Pfizer received the nod for the oral COVID-19 treatment ahead of&nbsp;<b>Merck &amp; Co., Inc.</b>, which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.</p>\n<p>The analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.</p>\n<p>Revenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.</p>\n<p>The impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.</p>\n<p>The drug label also didn't&nbsp;preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.</p>\n<p>Paxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.</p>\n<p><b>Paxlovid Should Remain A Steady Contributor, BofA Says:</b>There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.</p>\n<p>Longer-term, Paxlovid is likely to remain a steady contributor, the analyst said.</p>\n<p>\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.</p>\n<p>Government entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.</p>\n<p><b>Pfizer Price Action:</b>&nbsp;Pfizer shares closed&nbsp;lower 1.41% to $58.71 on&nbsp;Thursday.</p>\n<p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172289344","content_text":"Pfizer, Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.\nThe Pfizer Analysts:SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.\nBofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.\nBroad Label, Increased Supply To Give Pfizer Dominant Market Position:Pfizer received the nod for the oral COVID-19 treatment ahead of Merck & Co., Inc., which submitted its application for itsmolnupiravirmore than a month ahead of Pfizer, Porges said in a note.\nThe analyst sees the increase in Pfizer's expected supply of Paxlovid to 120 million courses next year as significant. The company will sell and distribute most of these courses, resulting in revenue well in excess of SVB Leerink's current forecast of $24 billion in Paxlovid sales in 2022 and $33 billion in 2023, the analyst said.\nRevenue contribution will drop to $10 billion in 2024, the analyst said. This total $67 billion in Paxlovid sales estimated for 2022-'24 is well above consensus, he added.\nThe impact of drug-drug interactions on Paxlovid uptake will be modest since many of the drugs on the list can be paused for the short duration of Paxlovid treatment without significant impact for patients, Porges said. Patients that will likely be excluded from Paxlovid use are those with severe liver or renal impairment and those who have uncontrolled HIV-1 infection, he added.\nThe drug label also didn't preclude pregnant women from Paxlovid treatment and painted a risk/benefit profile that was relatively benign compared to Merck's molnupiravir, which showed embryonic development and fetal growth risks in animals, the analyst said.\nPaxlovid has a better efficacy profile than some leading antibody therapies, and with some of the antibody therapies having lost efficacy against the omicron variant, Paxlovid will be a \"highly attractive option for physicians and patients,\" Porges said.\nPaxlovid Should Remain A Steady Contributor, BofA Says:There should be no problem selling every course of Paxlovid Pfizer makes in 2022, BofA analyst Meacham said. The lag time between production and shipping/revenue recognition means Pfizer won't recognize the revenue from every dose in 2022, he added.\nLonger-term, Paxlovid is likely to remain a steady contributor, the analyst said.\n\"We expect breakthrough infections to continue regularly in the endemic phase, and while a baseline level of immunity from vaccines and prior infections will limit severity, we expect treatment of COVID cases as they occur in high-risk individuals to be standard of care,\" Meacham said.\nGovernment entities are expected to stockpile Merck's pill and so initial sales will likely be there, the analyst said. Longer-term, Paxlovid will likely be the preferred agent, he added.\nPfizer Price Action: Pfizer shares closed lower 1.41% to $58.71 on Thursday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1399,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691256282,"gmtCreate":1640214821162,"gmtModify":1640214821485,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Hm","listText":"Hm","text":"Hm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691256282","repostId":"1116093171","repostType":4,"isVote":1,"tweetType":1,"viewCount":1938,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693261946,"gmtCreate":1640041950535,"gmtModify":1640041950909,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693261946","repostId":"2193761136","repostType":4,"isVote":1,"tweetType":1,"viewCount":2269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693980724,"gmtCreate":1639960621460,"gmtModify":1639960621757,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Go nio!","listText":"Go nio!","text":"Go nio!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693980724","repostId":"1172014877","repostType":4,"repost":{"id":"1172014877","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639960226,"share":"https://www.laohu8.com/m/news/1172014877?lang=&edition=full","pubTime":"2021-12-20 08:30","market":"us","language":"en","title":"Will Nio's Newly-launched ET5 Pose A Threat To Tesla's Model 3?","url":"https://stock-news.laohu8.com/highlight/detail?id=1172014877","media":"Benzinga","summary":"Chinese EV startup Nio, Inc. unveiled a midsize sedan named ET5, its fifth vehicle mode, at its annu","content":"<p>Chinese EV startup&nbsp;<b>Nio, Inc.</b>&nbsp;unveiled&nbsp;a midsize sedan named ET5, its fifth vehicle mode, at its annual Nio Day event held amid fanfare on Saturday.</p>\n<p>The EV has notched up record preorders, according to local media outlets.</p>\n<p>The ET5, which will be the cheapest vehicle in Nio's product lineup once it launches, is seen as a challenger to&nbsp;<b>Tesla, Inc.'s</b>&nbsp;Model 3 sedan.</p>\n<p><b>ET5 Vs. Model 3:</b>An ET5 fitted with a 75 kilowatt-hour, or kWh battery would have a China Light-Duty Vehicle Test Cycle, or CLTC, range of 550 km, Nio said at the launch event. In comparison, the Model 3 base model has an EPA driving range of 556 km.</p>\n<p>Nio's ET5 armed with the 150-kWh battery has a range of over 1,000 km.</p>\n<p>Nio said the ET5 will have a dual-motor system - a 150 kW induction motor on the front and a 210 kW PM motor at the rear – and has 360 kW maximum power output, 480 horsepower and 700 N-m peak torque. In comparison, Model 3 comes with the option of dual motor AWD.</p>\n<p>Nio's ET5 can accelerate from 0 to 100 km/h in 4.3 seconds, while the Model 3 is capable of accelerating from 0-60 mph (0-96.6 km/h) in about 3.1 seconds.</p>\n<p>The sedans of the two companies are comparable on pricing. The base model of ET5 starts with 328,000 yuan ($51,448) and under a Battery-as-a-Service scheme, the vehicle costs 258,000 yuan and a 980-yuan monthly subscription fee.</p>\n<p>The Giga Shanghai-made Model 3 vehicle is priced between 255,652 yuan and 339,900 yuan.</p>\n<p>On dimensions, the ET5, which is 4,790 mm (188.6 inches) long, 1,960 mm (77.2 inches) wide and 1,499 mm (59 inches) high, with a wheelbase of 2,999 mm (113.7 inches), is slightly bigger than the Model 3, which is 184.8 inches long, 72.8 inches wide and 56.4 inches tall, with a 113.2-inch wheelbase.</p>\n<p>Nio's ET5 draws much of its features from the pricier ET7 sedan the company announced at the start of the year. Other features incorporated in the ET5 include the Nio Autonomous Driving system, Nio Aquila Super Sensing and Nio Adam Super Computing systems. The NAD's full-suite of features will be available for a 680-yuan monthly subscription fee.</p>\n<p>The vehicle's sophisticated interior comprises a 10.2-inch HDR instrument cluster and a large, tablet-style screen on the center console. It also comes with Nio's PanoCinema, a panoramic digital cockpit featuring Augmented and Virtual reality tech.</p>\n<p><b>Why It's Important:</b>Tesla currently has a stronghold on the Chinese EV market, which is said to be the lynchpin to the overall Tesla growth story. In November, Tesla&nbsp;sold&nbsp;8,615 Model 3 units and 23,117 units of Model Y, taking its total China sales to 31,732 units.</p>\n<p>Globally, the Model 3 is Tesla's best-selling car. With Nio nurturing ambitions of a big international expansion, it remains to be seen if the ET5 can give the Model 3 a run for its money.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Nio's Newly-launched ET5 Pose A Threat To Tesla's Model 3?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Nio's Newly-launched ET5 Pose A Threat To Tesla's Model 3?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-20 08:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Chinese EV startup&nbsp;<b>Nio, Inc.</b>&nbsp;unveiled&nbsp;a midsize sedan named ET5, its fifth vehicle mode, at its annual Nio Day event held amid fanfare on Saturday.</p>\n<p>The EV has notched up record preorders, according to local media outlets.</p>\n<p>The ET5, which will be the cheapest vehicle in Nio's product lineup once it launches, is seen as a challenger to&nbsp;<b>Tesla, Inc.'s</b>&nbsp;Model 3 sedan.</p>\n<p><b>ET5 Vs. Model 3:</b>An ET5 fitted with a 75 kilowatt-hour, or kWh battery would have a China Light-Duty Vehicle Test Cycle, or CLTC, range of 550 km, Nio said at the launch event. In comparison, the Model 3 base model has an EPA driving range of 556 km.</p>\n<p>Nio's ET5 armed with the 150-kWh battery has a range of over 1,000 km.</p>\n<p>Nio said the ET5 will have a dual-motor system - a 150 kW induction motor on the front and a 210 kW PM motor at the rear – and has 360 kW maximum power output, 480 horsepower and 700 N-m peak torque. In comparison, Model 3 comes with the option of dual motor AWD.</p>\n<p>Nio's ET5 can accelerate from 0 to 100 km/h in 4.3 seconds, while the Model 3 is capable of accelerating from 0-60 mph (0-96.6 km/h) in about 3.1 seconds.</p>\n<p>The sedans of the two companies are comparable on pricing. The base model of ET5 starts with 328,000 yuan ($51,448) and under a Battery-as-a-Service scheme, the vehicle costs 258,000 yuan and a 980-yuan monthly subscription fee.</p>\n<p>The Giga Shanghai-made Model 3 vehicle is priced between 255,652 yuan and 339,900 yuan.</p>\n<p>On dimensions, the ET5, which is 4,790 mm (188.6 inches) long, 1,960 mm (77.2 inches) wide and 1,499 mm (59 inches) high, with a wheelbase of 2,999 mm (113.7 inches), is slightly bigger than the Model 3, which is 184.8 inches long, 72.8 inches wide and 56.4 inches tall, with a 113.2-inch wheelbase.</p>\n<p>Nio's ET5 draws much of its features from the pricier ET7 sedan the company announced at the start of the year. Other features incorporated in the ET5 include the Nio Autonomous Driving system, Nio Aquila Super Sensing and Nio Adam Super Computing systems. The NAD's full-suite of features will be available for a 680-yuan monthly subscription fee.</p>\n<p>The vehicle's sophisticated interior comprises a 10.2-inch HDR instrument cluster and a large, tablet-style screen on the center console. It also comes with Nio's PanoCinema, a panoramic digital cockpit featuring Augmented and Virtual reality tech.</p>\n<p><b>Why It's Important:</b>Tesla currently has a stronghold on the Chinese EV market, which is said to be the lynchpin to the overall Tesla growth story. In November, Tesla&nbsp;sold&nbsp;8,615 Model 3 units and 23,117 units of Model Y, taking its total China sales to 31,732 units.</p>\n<p>Globally, the Model 3 is Tesla's best-selling car. With Nio nurturing ambitions of a big international expansion, it remains to be seen if the ET5 can give the Model 3 a run for its money.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1172014877","content_text":"Chinese EV startup Nio, Inc. unveiled a midsize sedan named ET5, its fifth vehicle mode, at its annual Nio Day event held amid fanfare on Saturday.\nThe EV has notched up record preorders, according to local media outlets.\nThe ET5, which will be the cheapest vehicle in Nio's product lineup once it launches, is seen as a challenger to Tesla, Inc.'s Model 3 sedan.\nET5 Vs. Model 3:An ET5 fitted with a 75 kilowatt-hour, or kWh battery would have a China Light-Duty Vehicle Test Cycle, or CLTC, range of 550 km, Nio said at the launch event. In comparison, the Model 3 base model has an EPA driving range of 556 km.\nNio's ET5 armed with the 150-kWh battery has a range of over 1,000 km.\nNio said the ET5 will have a dual-motor system - a 150 kW induction motor on the front and a 210 kW PM motor at the rear – and has 360 kW maximum power output, 480 horsepower and 700 N-m peak torque. In comparison, Model 3 comes with the option of dual motor AWD.\nNio's ET5 can accelerate from 0 to 100 km/h in 4.3 seconds, while the Model 3 is capable of accelerating from 0-60 mph (0-96.6 km/h) in about 3.1 seconds.\nThe sedans of the two companies are comparable on pricing. The base model of ET5 starts with 328,000 yuan ($51,448) and under a Battery-as-a-Service scheme, the vehicle costs 258,000 yuan and a 980-yuan monthly subscription fee.\nThe Giga Shanghai-made Model 3 vehicle is priced between 255,652 yuan and 339,900 yuan.\nOn dimensions, the ET5, which is 4,790 mm (188.6 inches) long, 1,960 mm (77.2 inches) wide and 1,499 mm (59 inches) high, with a wheelbase of 2,999 mm (113.7 inches), is slightly bigger than the Model 3, which is 184.8 inches long, 72.8 inches wide and 56.4 inches tall, with a 113.2-inch wheelbase.\nNio's ET5 draws much of its features from the pricier ET7 sedan the company announced at the start of the year. Other features incorporated in the ET5 include the Nio Autonomous Driving system, Nio Aquila Super Sensing and Nio Adam Super Computing systems. The NAD's full-suite of features will be available for a 680-yuan monthly subscription fee.\nThe vehicle's sophisticated interior comprises a 10.2-inch HDR instrument cluster and a large, tablet-style screen on the center console. It also comes with Nio's PanoCinema, a panoramic digital cockpit featuring Augmented and Virtual reality tech.\nWhy It's Important:Tesla currently has a stronghold on the Chinese EV market, which is said to be the lynchpin to the overall Tesla growth story. In November, Tesla sold 8,615 Model 3 units and 23,117 units of Model Y, taking its total China sales to 31,732 units.\nGlobally, the Model 3 is Tesla's best-selling car. With Nio nurturing ambitions of a big international expansion, it remains to be seen if the ET5 can give the Model 3 a run for its money.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1811,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699437082,"gmtCreate":1639874858052,"gmtModify":1639874858362,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Please like ans comment","listText":"Please like ans comment","text":"Please like ans comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/699437082","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","kind":"news","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699640048,"gmtCreate":1639796239993,"gmtModify":1639796240312,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699640048","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","kind":"news","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":690559489,"gmtCreate":1639696378499,"gmtModify":1639696378820,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Sad.","listText":"Sad.","text":"Sad.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/690559489","repostId":"2192920942","repostType":4,"isVote":1,"tweetType":1,"viewCount":954,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607744812,"gmtCreate":1639609626029,"gmtModify":1639609626349,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good news?","listText":"Good news?","text":"Good news?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607744812","repostId":"2191994940","repostType":4,"isVote":1,"tweetType":1,"viewCount":480,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607810028,"gmtCreate":1639523894354,"gmtModify":1639523894622,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Nice!","listText":"Nice!","text":"Nice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607810028","repostId":"1111446051","repostType":4,"repost":{"id":"1111446051","kind":"news","pubTimestamp":1639523229,"share":"https://www.laohu8.com/m/news/1111446051?lang=&edition=full","pubTime":"2021-12-15 07:07","market":"us","language":"en","title":"Pfizer Says Its Covid-19 Pill Likely Works Against Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=1111446051","media":"The Wall Street Journal","summary":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-","content":"<p></p>\n<p>Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.</p>\n<p></p>\n<p>Pfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.</p>\n<p></p>\n<p>The positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.</p>\n<p></p>\n<p>“This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.</p>\n<p></p>\n<p>Meanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.</p>\n<p></p>\n<p>Paxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.</p>\n<p></p>\n<p>Study subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.</p>\n<p></p>\n<p>Both studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.</p>\n<p></p>\n<p>A lower viral load could mean less transmission of the virus.</p>\n<p></p>\n<p>Citing the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase &amp; Co. analysts estimated $18 billion in sales next year.</p>\n<p></p>\n<p>Pfizer shares rose 0.62% in Tuesday trading.</p>\n<p></p>\n<p>Doctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.</p>\n<p></p>\n<p>The emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.</p>\n<p></p>\n<p>To make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.</p>\n<p></p>\n<p>Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ</p>\n<p>Researchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.</p>\n<p></p>\n<p></p>\n<p>That is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.</p>\n<p></p>\n<p>The early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.</p>\n<p></p>\n<p>“Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”</p>\n<p></p>\n<p>Pfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.</p>\n<p></p>\n<p>In November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.</p>\n<p></p>\n<p>The FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.</p>\n<p></p>\n<p>In the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.</p>\n<p></p>\n<p>Nine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.</p>\n<p></p>\n<p>Researchers also reported the drug was 88% effective if taken within five days of symptoms.</p>\n<p></p>\n<p>The final study analysis of another oral antiviral, from Merck &amp; Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.</p>\n<p></p>\n<p>Separately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.</p>\n<p></p>\n<p>The company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.</p>\n<p></p>\n<p>Two of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.</p>\n<p></p>\n<p></p>\n<p>No subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.</p>\n<p></p>\n<p>Dr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Says Its Covid-19 Pill Likely Works Against Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Says Its Covid-19 Pill Likely Works Against Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-15 07:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.\n\nPfizer also said ...</p>\n\n<a href=\"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.wsj.com/articles/pfizer-says-its-covid-19-pill-likely-works-against-omicron-11639482302?mod=hp_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111446051","content_text":"Preliminary laboratory tests gave encouraging signs that Pfizer Inc.’s PFE 0.62% experimental Covid-19 pill for the newly infected could work against Omicron, the company said.\n\nPfizer also said Tuesday that a final analysis of late-stage study results confirmed the drug, named Paxlovid, was 89% effective at reducing the risk of hospitalization and death in adults at high risk of severe Covid-19.\n\nThe positive results come as the Food and Drug Administration reviews whether to clear use of Paxlovid in high-risk adults, a decision that could come before the end of the year.\n\n“This was a real home run, gives tremendous hope for another highly effective intervention,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.\n\nMeanwhile, a separate, preliminary analysis provided signs the drug may help people at low risk of severe Covid-19, such as vaccinated individuals who end up becoming sick.\n\nPaxlovid in the early study analysis reduced the risk of hospitalization and death by 70% in adults at low risk of severe Covid-19, though it failed to reduce or resolve their symptoms within four days.\n\nStudy subjects who were at high risk of developing severe disease had to have at least one characteristic or underlying health condition such as being obese or elderly. The other study included people who were either unvaccinated and at low risk of developing severe disease, such as young and healthy individuals, or vaccinated people with at least one risk factor for developing severe disease.\n\nBoth studies testing Paxlovid in people showed that the amount of virus, or viral load, in subjects who received the drug was significantly less than in the placebo groups, Pfizer said.\n\nA lower viral load could mean less transmission of the virus.\n\nCiting the findings, some analysts said Paxlovid was likely to become the Covid-19 drug of choice for newly infected adults seeking to avoid severe disease. JP Morgan Chase & Co. analysts estimated $18 billion in sales next year.\n\nPfizer shares rose 0.62% in Tuesday trading.\n\nDoctors and health experts have been looking for an antiviral like Paxlovid, which people could easily take at home within several days of symptoms emerging to prevent their cases from turning serious and requiring hospitalization.\n\nThe emergence of Omicron has shadowed the approach of such antivirals, however, because of uncertainty whether the new strain could elude treatments and vaccines.\n\nTo make an assessment, drugmakers have been studying whether authorized and experimental Covid-19 drugs and vaccines are effective against Omicron.\n\nDoctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ\nResearchers suspected Pfizer’s pill would hold up well because it stops the virus by blocking the activity of a key enzyme, known as protease, that the virus needs to replicate and isn’t believed to be mutated in Omicron.\n\n\nThat is different from Covid-19 vaccines and some treatments that target a different part of the virus, the spike protein, that is the site of many Omicron mutations.\n\nThe early Pfizer laboratory tests showed that Paxlovid blocked the protease enzyme in Omicron, as well as other variants of concern, Dr. Dolsten said.\n\n“Without the protease functioning, the virus can’t replicate and cause disease,” Dr. Dolsten said. “I’m very convinced that the effects on Omicron by Paxlovid will be very substantial.”\n\nPfizer said it plans on performing more testing to measure Paxlovid’s effectiveness against the variant.\n\nIn November, Pfizer said an early look at a key study found Paxlovid was 89% effective at reducing the risk of hospitalization and death in high-risk adults.\n\nThe FDA has been waiting for the final results before making an authorization decision, Pfizer Chief Executive Albert Bourla said last week at The Wall Street Journal’s CEO Council.\n\nIn the final analysis, five of the 697 high-risk subjects who received the drug within three days of symptoms were hospitalized or died from Covid-19, compared with 44 out of 682 subjects who received a placebo, Pfizer said.\n\nNine study volunteers who received a placebo died, compared with none in the treatment arm, the company said.\n\nResearchers also reported the drug was 88% effective if taken within five days of symptoms.\n\nThe final study analysis of another oral antiviral, from Merck & Co. and partner Ridgeback Biotherapeutics LP, showed a 30% risk reduction, lower than the 50% found during an early look.\n\nSeparately, Pfizer has been testing Paxlovid’s effectiveness in people at low risk of developing severe disease, including some who were vaccinated.\n\nThe company’s preliminary look at the results found Paxlovid failed to resolve or consistently reduce self-reported symptoms within four days, which was the study’s main goal and a way of determining whether an antiviral is effective.\n\nTwo of the 333 low-risk subjects who got Paxlovid were hospitalized, however, compared with eight of 329 subjects who received a placebo, resulting in the 70% efficacy, Pfizer said.\n\n\nNo subjects had died from Covid-19 in the analysis, which looked at how about 45% of the total number of subjects targeted for the study fared.\n\nDr. Dolsten said Pfizer planned to discuss with health authorities in the U.S. and other countries about potentially making the drug available to low-risk people, and whether Pfizer should do more testing.","news_type":1},"isVote":1,"tweetType":1,"viewCount":557,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604495277,"gmtCreate":1639437013312,"gmtModify":1639437013626,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Sad","listText":"Sad","text":"Sad","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604495277","repostId":"2191165981","repostType":4,"isVote":1,"tweetType":1,"viewCount":602,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604683464,"gmtCreate":1639386871800,"gmtModify":1639386872085,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Sigh","listText":"Sigh","text":"Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/604683464","repostId":"1177222740","repostType":4,"repost":{"id":"1177222740","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639386759,"share":"https://www.laohu8.com/m/news/1177222740?lang=&edition=full","pubTime":"2021-12-13 17:12","market":"us","language":"en","title":"Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177222740","media":"Tiger Newspress","summary":"Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more t","content":"<p>Vaccine&nbsp;stocks&nbsp;jumped&nbsp;in&nbsp;premarket&nbsp;trading,with&nbsp;Novavax&nbsp;rising&nbsp;over&nbsp;5%&nbsp;and&nbsp;BioNTech&nbsp;SE&nbsp;rising&nbsp;more&nbsp;than&nbsp;3%.<img src=\"https://static.tigerbbs.com/bdf47380f0d8775b43c9143423a79e00\" tg-width=\"770\" tg-height=\"560\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/1b5e3fff3bd7076c87237eb4c56b1db0\" tg-width=\"771\" tg-height=\"562\" referrerpolicy=\"no-referrer\">Three doses of the Pfizer-BioNTechCOVID-19vaccine, BNT162b2 have been shown in a preliminary study to neutralize the Omicron variant.</p>\n<p>In a&nbsp;press release, Pfizer and BioNTech have announced that serum antibodies induced after three doses of their COVID-19 vaccine (BNT162b2) are able to neutralize the Omicron variant.</p>\n<p>The company’s laboratory study involved testing human sera obtained from the blood of individuals who had received two or three 30-µg doses of the BNT162B2 using a&nbsp;pseudovirus&nbsp;neutralization test, which was&nbsp;used to study the effect of antibodies to neutralize the capability of viruses to enter cells and thus prevent infection. The sera were collected from subjects 3 weeks after receiving the second dose or one month after receiving the third dose of their vaccine.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 17:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine&nbsp;stocks&nbsp;jumped&nbsp;in&nbsp;premarket&nbsp;trading,with&nbsp;Novavax&nbsp;rising&nbsp;over&nbsp;5%&nbsp;and&nbsp;BioNTech&nbsp;SE&nbsp;rising&nbsp;more&nbsp;than&nbsp;3%.<img src=\"https://static.tigerbbs.com/bdf47380f0d8775b43c9143423a79e00\" tg-width=\"770\" tg-height=\"560\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/1b5e3fff3bd7076c87237eb4c56b1db0\" tg-width=\"771\" tg-height=\"562\" referrerpolicy=\"no-referrer\">Three doses of the Pfizer-BioNTechCOVID-19vaccine, BNT162b2 have been shown in a preliminary study to neutralize the Omicron variant.</p>\n<p>In a&nbsp;press release, Pfizer and BioNTech have announced that serum antibodies induced after three doses of their COVID-19 vaccine (BNT162b2) are able to neutralize the Omicron variant.</p>\n<p>The company’s laboratory study involved testing human sera obtained from the blood of individuals who had received two or three 30-µg doses of the BNT162B2 using a&nbsp;pseudovirus&nbsp;neutralization test, which was&nbsp;used to study the effect of antibodies to neutralize the capability of viruses to enter cells and thus prevent infection. The sera were collected from subjects 3 weeks after receiving the second dose or one month after receiving the third dose of their vaccine.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1177222740","content_text":"Vaccine stocks jumped in premarket trading,with Novavax rising over 5% and BioNTech SE rising more than 3%.Three doses of the Pfizer-BioNTechCOVID-19vaccine, BNT162b2 have been shown in a preliminary study to neutralize the Omicron variant.\nIn a press release, Pfizer and BioNTech have announced that serum antibodies induced after three doses of their COVID-19 vaccine (BNT162b2) are able to neutralize the Omicron variant.\nThe company’s laboratory study involved testing human sera obtained from the blood of individuals who had received two or three 30-µg doses of the BNT162B2 using a pseudovirus neutralization test, which was used to study the effect of antibodies to neutralize the capability of viruses to enter cells and thus prevent infection. The sera were collected from subjects 3 weeks after receiving the second dose or one month after receiving the third dose of their vaccine.","news_type":1},"isVote":1,"tweetType":1,"viewCount":810,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605255938,"gmtCreate":1639183998473,"gmtModify":1639184049682,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605255938","repostId":"2190296066","repostType":4,"isVote":1,"tweetType":1,"viewCount":614,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602892245,"gmtCreate":1639005195847,"gmtModify":1639005222611,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602892245","repostId":"2190169579","repostType":4,"isVote":1,"tweetType":1,"viewCount":720,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606432743,"gmtCreate":1638918822514,"gmtModify":1638918923096,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606432743","repostId":"1142645155","repostType":4,"repost":{"id":"1142645155","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638890012,"share":"https://www.laohu8.com/m/news/1142645155?lang=&edition=full","pubTime":"2021-12-07 23:13","market":"us","language":"en","title":"Pinduoduo shares surged 11% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142645155","media":"Tiger Newspress","summary":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating ratin","content":"<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pinduoduo shares surged 11% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPinduoduo shares surged 11% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pinduoduo shares surged 11% in morning trading&nbsp;after&nbsp;Macquarie gave pinduoduo a market beating rating with a target price of $95.</p>\n<p><img src=\"https://static.tigerbbs.com/38c15dca491bd8741f8ac3af099bdeb7\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PDD":"拼多多"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142645155","content_text":"Pinduoduo shares surged 11% in morning trading after Macquarie gave pinduoduo a market beating rating with a target price of $95.","news_type":1},"isVote":1,"tweetType":1,"viewCount":621,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606399368,"gmtCreate":1638832419855,"gmtModify":1638832420114,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Ok pls like","listText":"Ok pls like","text":"Ok pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/606399368","repostId":"2189686835","repostType":4,"isVote":1,"tweetType":1,"viewCount":645,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608529767,"gmtCreate":1638761628160,"gmtModify":1638761628295,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Boom!","listText":"Boom!","text":"Boom!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/608529767","repostId":"1185586969","repostType":4,"repost":{"id":"1185586969","kind":"news","pubTimestamp":1638761076,"share":"https://www.laohu8.com/m/news/1185586969?lang=&edition=full","pubTime":"2021-12-06 11:24","market":"us","language":"en","title":"Former Netflix engineer and accomplice sentenced to prison for insider trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1185586969","media":"CNN Business","summary":"New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Frida","content":"<p>New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.</p>\n<p>Their roles in an insider trading ring illegally generated more than $3 million, US attorney Nick Brown said.</p>\n<p>Sung Mo Jun, 49, was sentenced to two years in prison and a $15,000 fine. His co-conspirator Junwoo Chon, 50, was sentenced to 14 months in prison and a $10,000 fine. Both are from Bellevue, Washington and pleaded guilty in August. CNN has reached out to attorneys for Jun and Chon for comment.</p>\n<p>\"For people in the high-tech industry, they will clearly know that there are consequences -- including prison time -- for this activity,\" US District Judge Richard A. Jones said.</p>\n<p>Insider trading is the buying or selling of a company's securities with information not available to the public. It is illegal in the United States.</p>\n<p>Brown, the US attorney, said in a press release both men were financially secure and had well-paying jobs, but \"greed drove them to break the law to increase their own wealth.\"</p>\n<p>According to case records, Jun worked at Netflix from July 2016 to February 2017, during which time he shared confidential subscriber data with his brother, Joon Jun, and with Chon.</p>\n<p>After leaving Netflix, Sung Mo Jun continued sharing information and began making trades himself using data received from another Netflix software engineer, Ayden Lee, case records showed.</p>\n<p>Jun is forfeiting $495,188 to the US government and Chon is forfeiting $1,582,885. Both must complete 50 hours of community service and will be on one year of supervised release after they are released from prison.</p>\n<p>\"What I did was foolish, wrong, illegal.... I have no excuse. I disappointed many people,\" Sung Mo Jun told the court at his sentencing.</p>\n<p>The other two conspirators, Joon Jun and Lee, will be sentenced next year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Former Netflix engineer and accomplice sentenced to prison for insider trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFormer Netflix engineer and accomplice sentenced to prison for insider trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 11:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.\n...</p>\n\n<a href=\"https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185586969","content_text":"New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.\nTheir roles in an insider trading ring illegally generated more than $3 million, US attorney Nick Brown said.\nSung Mo Jun, 49, was sentenced to two years in prison and a $15,000 fine. His co-conspirator Junwoo Chon, 50, was sentenced to 14 months in prison and a $10,000 fine. Both are from Bellevue, Washington and pleaded guilty in August. CNN has reached out to attorneys for Jun and Chon for comment.\n\"For people in the high-tech industry, they will clearly know that there are consequences -- including prison time -- for this activity,\" US District Judge Richard A. Jones said.\nInsider trading is the buying or selling of a company's securities with information not available to the public. It is illegal in the United States.\nBrown, the US attorney, said in a press release both men were financially secure and had well-paying jobs, but \"greed drove them to break the law to increase their own wealth.\"\nAccording to case records, Jun worked at Netflix from July 2016 to February 2017, during which time he shared confidential subscriber data with his brother, Joon Jun, and with Chon.\nAfter leaving Netflix, Sung Mo Jun continued sharing information and began making trades himself using data received from another Netflix software engineer, Ayden Lee, case records showed.\nJun is forfeiting $495,188 to the US government and Chon is forfeiting $1,582,885. Both must complete 50 hours of community service and will be on one year of supervised release after they are released from prison.\n\"What I did was foolish, wrong, illegal.... I have no excuse. I disappointed many people,\" Sung Mo Jun told the court at his sentencing.\nThe other two conspirators, Joon Jun and Lee, will be sentenced next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":114752661,"gmtCreate":1623107739853,"gmtModify":1634036987584,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Wow good news","listText":"Wow good news","text":"Wow good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/114752661","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://www.laohu8.com/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":313,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":819773630,"gmtCreate":1630110939120,"gmtModify":1704956047936,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Huh nice","listText":"Huh nice","text":"Huh nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/819773630","repostId":"2162907389","repostType":4,"isVote":1,"tweetType":1,"viewCount":472,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":355869243,"gmtCreate":1617061145882,"gmtModify":1634522911100,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Hope this means it goes up! Like and comment pls","listText":"Hope this means it goes up! Like and comment pls","text":"Hope this means it goes up! Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/355869243","repostId":"2123518862","repostType":4,"repost":{"id":"2123518862","kind":"news","pubTimestamp":1617030636,"share":"https://www.laohu8.com/m/news/2123518862?lang=&edition=full","pubTime":"2021-03-29 23:10","market":"us","language":"en","title":"Nio, XPeng File For Hong Kong Listings: Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2123518862","media":"Benzinga","summary":"NIO Limited  and XPeng Inc.  have made further progress in their endeavor to pursue a listing outside of the U.S.What Happened: Nio and XPeng have filed regulatory applications to list their shares on the Hong Kong stock exchange, local Chinese media outlet cls.cn reported, citing people familiar with the matter.Li Auto Inc.  has yet to submit its application, the report said.Nio and XPeng spokespeople declined to comment on the report when contacted by Benzinga.The news of the Chinese EV trio —","content":"<p><img src=\"https://static.tigerbbs.com/1f1e2190d1785eedb1d2adbc9d64e643\" tg-width=\"600\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p><b>NIO Limited</b> (NYSE: NIO) and <b>XPeng Inc. </b>(NYSE: XPEV) have made further progress in their endeavor to pursue a listing outside of the U.S.</p>\n<p><b>What Happened:</b> Nio and XPeng have filed regulatory applications to list their shares on the Hong Kong stock exchange, local Chinese media outlet cls.cn reported, citing people familiar with the matter.</p>\n<p><b>Li Auto Inc.</b> (NASDAQ: LI) has&nbsp;yet to submit its application, the report said.</p>\n<p>Nio and XPeng spokespeople declined to comment on the report when contacted by Benzinga.</p>\n<p>The news of the Chinese EV trio —&nbsp;Nio, XPeng and Li Auto —&nbsp;contemplating Hong Kong listings was initially broken by Reuters in early March. The Reuters report said the companies are seeking to offer 5% of their expanded share capital in a bid to raise a cumulative $5 billion.</p>\n<p>Later on March 22, an IFR report said the companies have hired investment managers to assist with the offerings. The report further said Nio would undertake&nbsp;a secondary listing, while XPeng and Li Auto are forced to file for primary dual listings due to regulatory restrictions.</p>\n<p><b>Why It's Important:</b> The Chinese EV makers, which were among the best-performing stocks of 2020, have not had a smooth ride so&nbsp;far this year.</p>\n<p>Apart from market-wide factors that have pressured these stocks, the companies also witnessed a slowdown in sales in February. Indications that sales could remain pressured amid a chip supply shortage are intensifying the weakness further.</p>\n<p>Nio is shutting down production at its&nbsp;Hefei plant for five days&nbsp;starting Monday. It also lowered its deliveries guidance for the first quarter.</p>\n<p>A domestic listing is expected to expand the investor base of the companies, creating access to further capital. Additionally, it will serve to remove the overhang of a U.S. regulatory clampdown on U.S.-listed Chinese companies.</p>\n<p><b>LI, NIO, XPEV Price Action:</b> In premarket trading, Nio shares were down 2.32% to $35.29, XPeng was receding 1.31% to $31.72&nbsp;and Li Auto shares were moving down 1.22% to $23.41.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio, XPeng File For Hong Kong Listings: Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio, XPeng File For Hong Kong Listings: Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-29 23:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/nio-xpeng-file-hong-kong-121036694.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NIO Limited (NYSE: NIO) and XPeng Inc. (NYSE: XPEV) have made further progress in their endeavor to pursue a listing outside of the U.S.\nWhat Happened: Nio and XPeng have filed regulatory applications...</p>\n\n<a href=\"https://finance.yahoo.com/news/nio-xpeng-file-hong-kong-121036694.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/d891d4259c070317fc2a1875e00ebf81","relate_stocks":{"LI":"理想汽车","XPEV":"小鹏汽车","NIO":"蔚来"},"source_url":"https://finance.yahoo.com/news/nio-xpeng-file-hong-kong-121036694.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2123518862","content_text":"NIO Limited (NYSE: NIO) and XPeng Inc. (NYSE: XPEV) have made further progress in their endeavor to pursue a listing outside of the U.S.\nWhat Happened: Nio and XPeng have filed regulatory applications to list their shares on the Hong Kong stock exchange, local Chinese media outlet cls.cn reported, citing people familiar with the matter.\nLi Auto Inc. (NASDAQ: LI) has yet to submit its application, the report said.\nNio and XPeng spokespeople declined to comment on the report when contacted by Benzinga.\nThe news of the Chinese EV trio — Nio, XPeng and Li Auto — contemplating Hong Kong listings was initially broken by Reuters in early March. The Reuters report said the companies are seeking to offer 5% of their expanded share capital in a bid to raise a cumulative $5 billion.\nLater on March 22, an IFR report said the companies have hired investment managers to assist with the offerings. The report further said Nio would undertake a secondary listing, while XPeng and Li Auto are forced to file for primary dual listings due to regulatory restrictions.\nWhy It's Important: The Chinese EV makers, which were among the best-performing stocks of 2020, have not had a smooth ride so far this year.\nApart from market-wide factors that have pressured these stocks, the companies also witnessed a slowdown in sales in February. Indications that sales could remain pressured amid a chip supply shortage are intensifying the weakness further.\nNio is shutting down production at its Hefei plant for five days starting Monday. It also lowered its deliveries guidance for the first quarter.\nA domestic listing is expected to expand the investor base of the companies, creating access to further capital. Additionally, it will serve to remove the overhang of a U.S. regulatory clampdown on U.S.-listed Chinese companies.\nLI, NIO, XPEV Price Action: In premarket trading, Nio shares were down 2.32% to $35.29, XPeng was receding 1.31% to $31.72 and Li Auto shares were moving down 1.22% to $23.41.","news_type":1},"isVote":1,"tweetType":1,"viewCount":275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":858864332,"gmtCreate":1635037181972,"gmtModify":1635037182418,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/858864332","repostId":"1197815871","repostType":4,"repost":{"id":"1197815871","kind":"news","pubTimestamp":1635036807,"share":"https://www.laohu8.com/m/news/1197815871?lang=&edition=full","pubTime":"2021-10-24 08:53","market":"us","language":"en","title":"Consumer Confidence Is Falling. Why That’s Ominous for Stocks.","url":"https://stock-news.laohu8.com/highlight/detail?id=1197815871","media":"Barrons","summary":"Consumers are sending worrisome signals that investors aren’t heeding. It’s time to pay attention.\nT","content":"<p>Consumers are sending worrisome signals that investors aren’t heeding. It’s time to pay attention.</p>\n<p>The stock market and consumer sentiment usually rise and fall in tandem. Take the past 18 months. Ultraloose global monetary policy, record levels of fiscal stimulus, and rising earnings forecasts have sent stocks to successive highs. The same stimulative forces, plus a pandemic that curtailed social activity, helped U.S. consumers amass more than $2 trillion in savings, even as the labor market tightened and wages climbed. Those stock market gains made consumers feel even more flush, and flush consumers made investors more bullish.</p>\n<p>Recently, though, the correlation has broken down. Consumers have become far less cheery while the stock market has marched higher, with the S&amp;P 500 index hitting an all-time high on Thursday. As Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, notes, the University of Michigan Consumer Sentiment index bounced up only slightly in September—to its March 2020 pandemic low—after dropping in August to the worst level since 2012. The Conference Board’s Consumer Confidence Index similarly tumbled.</p>\n<p>The gap between those readings and the change in the stock market remains uncharacteristically wide, Shalett says. The difference between current readings and future expectations is also widening, suggesting that consumers don’t see their concerns as temporary. The confidence gap has persisted even as the latest wave of Covid-19 infections appears to have peaked, meaning there’s more to the story than the virus.</p>\n<p>So, who is right? Shalett leans toward the consumer’s view, and she’s not alone.</p>\n<p>In a paper earlier this month, David Blanchflower, an economics professor at Dartmouth College and a former external member of the Bank of England’s monetary-policy committee, and Alex Bryson, a professor of quantitative social science at University College London, wrote about what they call “the economics of walking about.” The idea: that people on the ground possess information about economic trends based on their own experiences and the experiences of those they know, which allows them to assess future economic trends.</p>\n<p>Their conclusion: Economic shocks are hard to predict, but qualitative metrics about consumer expectations are predictive of downturns. They show that consumer-expectations indexes from both the University of Michigan and the Conference Board predict downturns up to 18 months in advance in the U.S. They find that all recessions since the 1980s have been predicted by at least 10-point drops in those indexes.</p>\n<p>The Michigan gauge peaked in June 2021 and fell by 18 points by August, while the Conference Board measure peaked in March 2021 and then fell by 26 points through September 2021, say Blanchflower and Bryson. While they call the economic situation in 2021 “exceptional,” downshifts in consumer expectations in the past six months suggest that the U.S. economy is entering recession now, they say.</p>\n<p>“This is a bold call, and not consistent with consensus,” say Blanchflower and Bryson. “However, missing the declines in these variables in 2007, as most policy makers and economists did, proved fatal.”</p>\n<p>The reasons behind souring sentiment are at least as important as the decline itself. Surveys show that inflation is consumers’ top concern, even if the Federal Reserve continues to dismiss building pricing pressures.</p>\n<p>Consider retail sales, one series that Wall Street points to as evidence of buoyant consumers. Since March, when the last round of stimulus checks was sent, retail sales are up just 0.4%, while the consumer price index has risen 3.6%, notes Peter Boockvar, chief investment officer at Bleakley Advisory Group. “One can argue that all of the retail sales since March, and then some, is inflation and not volumes,” Boockvar says.</p>\n<p>Widespread shortages mean there is less to buy, but risk lies in assuming that demand is simply delayed. If consumers grow increasingly wary as they wait for cars, houses, and other items to become available—or affordable—potential consumption may be lost.</p>\n<p>People are also worried about the job market, says University of Michigan economist Richard Curtin, despite ubiquitous help-wanted signs and fast wage growth. Workers may have written off more permanently jobs that became riskier during the pandemic and don’t pay enough to cover costs, as wage gains still haven’t kept pace with consumer price inflation. Many are forging new paths—new-business formation continues to explode—reinforcing the idea that the labor shortage isn’t so temporary.</p>\n<p>What is the upshot for investors? “If consumer sentiment doesn’t quickly improve, it could be a signal of market weakness that would be sparked by disappointing earnings, weaker spending, and higher savings rates,” says Shalett.</p>\n<p>There are places where a lasting labor shortage and waning consumer confidence intersect, she says, recommending that investors look for companies that have tapped into more resilient demand and are less dependent on labor. She prefers business-to-business companies over those that sell directly to consumers, and says the best places to stock-pick are in banking, energy, and industrials.</p>\n<p>Consumers’ current funk could be transitory. But the funk itself, and the reasons for it, send an ominous message that investors shouldn’t ignore.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consumer Confidence Is Falling. Why That’s Ominous for Stocks.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsumer Confidence Is Falling. Why That’s Ominous for Stocks.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-24 08:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/us-economy-stock-market-consumer-confidence-51634943248?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Consumers are sending worrisome signals that investors aren’t heeding. It’s time to pay attention.\nThe stock market and consumer sentiment usually rise and fall in tandem. Take the past 18 months. ...</p>\n\n<a href=\"https://www.barrons.com/articles/us-economy-stock-market-consumer-confidence-51634943248?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/us-economy-stock-market-consumer-confidence-51634943248?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197815871","content_text":"Consumers are sending worrisome signals that investors aren’t heeding. It’s time to pay attention.\nThe stock market and consumer sentiment usually rise and fall in tandem. Take the past 18 months. Ultraloose global monetary policy, record levels of fiscal stimulus, and rising earnings forecasts have sent stocks to successive highs. The same stimulative forces, plus a pandemic that curtailed social activity, helped U.S. consumers amass more than $2 trillion in savings, even as the labor market tightened and wages climbed. Those stock market gains made consumers feel even more flush, and flush consumers made investors more bullish.\nRecently, though, the correlation has broken down. Consumers have become far less cheery while the stock market has marched higher, with the S&P 500 index hitting an all-time high on Thursday. As Lisa Shalett, chief investment officer at Morgan Stanley Wealth Management, notes, the University of Michigan Consumer Sentiment index bounced up only slightly in September—to its March 2020 pandemic low—after dropping in August to the worst level since 2012. The Conference Board’s Consumer Confidence Index similarly tumbled.\nThe gap between those readings and the change in the stock market remains uncharacteristically wide, Shalett says. The difference between current readings and future expectations is also widening, suggesting that consumers don’t see their concerns as temporary. The confidence gap has persisted even as the latest wave of Covid-19 infections appears to have peaked, meaning there’s more to the story than the virus.\nSo, who is right? Shalett leans toward the consumer’s view, and she’s not alone.\nIn a paper earlier this month, David Blanchflower, an economics professor at Dartmouth College and a former external member of the Bank of England’s monetary-policy committee, and Alex Bryson, a professor of quantitative social science at University College London, wrote about what they call “the economics of walking about.” The idea: that people on the ground possess information about economic trends based on their own experiences and the experiences of those they know, which allows them to assess future economic trends.\nTheir conclusion: Economic shocks are hard to predict, but qualitative metrics about consumer expectations are predictive of downturns. They show that consumer-expectations indexes from both the University of Michigan and the Conference Board predict downturns up to 18 months in advance in the U.S. They find that all recessions since the 1980s have been predicted by at least 10-point drops in those indexes.\nThe Michigan gauge peaked in June 2021 and fell by 18 points by August, while the Conference Board measure peaked in March 2021 and then fell by 26 points through September 2021, say Blanchflower and Bryson. While they call the economic situation in 2021 “exceptional,” downshifts in consumer expectations in the past six months suggest that the U.S. economy is entering recession now, they say.\n“This is a bold call, and not consistent with consensus,” say Blanchflower and Bryson. “However, missing the declines in these variables in 2007, as most policy makers and economists did, proved fatal.”\nThe reasons behind souring sentiment are at least as important as the decline itself. Surveys show that inflation is consumers’ top concern, even if the Federal Reserve continues to dismiss building pricing pressures.\nConsider retail sales, one series that Wall Street points to as evidence of buoyant consumers. Since March, when the last round of stimulus checks was sent, retail sales are up just 0.4%, while the consumer price index has risen 3.6%, notes Peter Boockvar, chief investment officer at Bleakley Advisory Group. “One can argue that all of the retail sales since March, and then some, is inflation and not volumes,” Boockvar says.\nWidespread shortages mean there is less to buy, but risk lies in assuming that demand is simply delayed. If consumers grow increasingly wary as they wait for cars, houses, and other items to become available—or affordable—potential consumption may be lost.\nPeople are also worried about the job market, says University of Michigan economist Richard Curtin, despite ubiquitous help-wanted signs and fast wage growth. Workers may have written off more permanently jobs that became riskier during the pandemic and don’t pay enough to cover costs, as wage gains still haven’t kept pace with consumer price inflation. Many are forging new paths—new-business formation continues to explode—reinforcing the idea that the labor shortage isn’t so temporary.\nWhat is the upshot for investors? “If consumer sentiment doesn’t quickly improve, it could be a signal of market weakness that would be sparked by disappointing earnings, weaker spending, and higher savings rates,” says Shalett.\nThere are places where a lasting labor shortage and waning consumer confidence intersect, she says, recommending that investors look for companies that have tapped into more resilient demand and are less dependent on labor. She prefers business-to-business companies over those that sell directly to consumers, and says the best places to stock-pick are in banking, energy, and industrials.\nConsumers’ current funk could be transitory. But the funk itself, and the reasons for it, send an ominous message that investors shouldn’t ignore.","news_type":1},"isVote":1,"tweetType":1,"viewCount":360,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":818721339,"gmtCreate":1630451524921,"gmtModify":1631885535725,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/818721339","repostId":"2164869989","repostType":4,"isVote":1,"tweetType":1,"viewCount":150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":821452407,"gmtCreate":1633778555079,"gmtModify":1633778555241,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Thanks. Good to know.&nbsp;","listText":"Thanks. Good to know.&nbsp;","text":"Thanks. Good to know.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/821452407","repostId":"2174920514","repostType":4,"isVote":1,"tweetType":1,"viewCount":286,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":815467686,"gmtCreate":1630714381645,"gmtModify":1631885535684,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good I guess","listText":"Good I guess","text":"Good I guess","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":11,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/815467686","repostId":"2164803577","repostType":4,"isVote":1,"tweetType":1,"viewCount":223,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":178420951,"gmtCreate":1626832773173,"gmtModify":1633770571734,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/178420951","repostId":"2153561380","repostType":4,"isVote":1,"tweetType":1,"viewCount":263,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":848156875,"gmtCreate":1635985204628,"gmtModify":1635985205076,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/848156875","repostId":"2180636457","repostType":4,"isVote":1,"tweetType":1,"viewCount":137,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699640048,"gmtCreate":1639796239993,"gmtModify":1639796240312,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/699640048","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","kind":"news","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1155,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608529767,"gmtCreate":1638761628160,"gmtModify":1638761628295,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Boom!","listText":"Boom!","text":"Boom!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/608529767","repostId":"1185586969","repostType":4,"repost":{"id":"1185586969","kind":"news","pubTimestamp":1638761076,"share":"https://www.laohu8.com/m/news/1185586969?lang=&edition=full","pubTime":"2021-12-06 11:24","market":"us","language":"en","title":"Former Netflix engineer and accomplice sentenced to prison for insider trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1185586969","media":"CNN Business","summary":"New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Frida","content":"<p>New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.</p>\n<p>Their roles in an insider trading ring illegally generated more than $3 million, US attorney Nick Brown said.</p>\n<p>Sung Mo Jun, 49, was sentenced to two years in prison and a $15,000 fine. His co-conspirator Junwoo Chon, 50, was sentenced to 14 months in prison and a $10,000 fine. Both are from Bellevue, Washington and pleaded guilty in August. CNN has reached out to attorneys for Jun and Chon for comment.</p>\n<p>\"For people in the high-tech industry, they will clearly know that there are consequences -- including prison time -- for this activity,\" US District Judge Richard A. Jones said.</p>\n<p>Insider trading is the buying or selling of a company's securities with information not available to the public. It is illegal in the United States.</p>\n<p>Brown, the US attorney, said in a press release both men were financially secure and had well-paying jobs, but \"greed drove them to break the law to increase their own wealth.\"</p>\n<p>According to case records, Jun worked at Netflix from July 2016 to February 2017, during which time he shared confidential subscriber data with his brother, Joon Jun, and with Chon.</p>\n<p>After leaving Netflix, Sung Mo Jun continued sharing information and began making trades himself using data received from another Netflix software engineer, Ayden Lee, case records showed.</p>\n<p>Jun is forfeiting $495,188 to the US government and Chon is forfeiting $1,582,885. Both must complete 50 hours of community service and will be on one year of supervised release after they are released from prison.</p>\n<p>\"What I did was foolish, wrong, illegal.... I have no excuse. I disappointed many people,\" Sung Mo Jun told the court at his sentencing.</p>\n<p>The other two conspirators, Joon Jun and Lee, will be sentenced next year.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Former Netflix engineer and accomplice sentenced to prison for insider trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFormer Netflix engineer and accomplice sentenced to prison for insider trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-06 11:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html><strong>CNN Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.\n...</p>\n\n<a href=\"https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NFLX":"奈飞"},"source_url":"https://edition.cnn.com/2021/12/04/business/netflix-insider-trading-sentence/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1185586969","content_text":"New York, NY (CNN)A former Netflix (NFLX) software engineer and his best friend were sentenced Friday for securities fraud, the US Attorney's Office in the Western District of Washington announced.\nTheir roles in an insider trading ring illegally generated more than $3 million, US attorney Nick Brown said.\nSung Mo Jun, 49, was sentenced to two years in prison and a $15,000 fine. His co-conspirator Junwoo Chon, 50, was sentenced to 14 months in prison and a $10,000 fine. Both are from Bellevue, Washington and pleaded guilty in August. CNN has reached out to attorneys for Jun and Chon for comment.\n\"For people in the high-tech industry, they will clearly know that there are consequences -- including prison time -- for this activity,\" US District Judge Richard A. Jones said.\nInsider trading is the buying or selling of a company's securities with information not available to the public. It is illegal in the United States.\nBrown, the US attorney, said in a press release both men were financially secure and had well-paying jobs, but \"greed drove them to break the law to increase their own wealth.\"\nAccording to case records, Jun worked at Netflix from July 2016 to February 2017, during which time he shared confidential subscriber data with his brother, Joon Jun, and with Chon.\nAfter leaving Netflix, Sung Mo Jun continued sharing information and began making trades himself using data received from another Netflix software engineer, Ayden Lee, case records showed.\nJun is forfeiting $495,188 to the US government and Chon is forfeiting $1,582,885. Both must complete 50 hours of community service and will be on one year of supervised release after they are released from prison.\n\"What I did was foolish, wrong, illegal.... I have no excuse. I disappointed many people,\" Sung Mo Jun told the court at his sentencing.\nThe other two conspirators, Joon Jun and Lee, will be sentenced next year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":550,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":149908802,"gmtCreate":1625699448106,"gmtModify":1633938341013,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Comment and like pls","listText":"Comment and like pls","text":"Comment and like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/149908802","repostId":"2149313903","repostType":4,"isVote":1,"tweetType":1,"viewCount":114,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":153330191,"gmtCreate":1625009393413,"gmtModify":1633946008144,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Die la","listText":"Die la","text":"Die la","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/153330191","repostId":"2147603368","repostType":4,"isVote":1,"tweetType":1,"viewCount":490,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":817269327,"gmtCreate":1630970211369,"gmtModify":1631885535666,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Haha&nbsp;","listText":"Haha&nbsp;","text":"Haha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/817269327","repostId":"1148981857","repostType":4,"isVote":1,"tweetType":1,"viewCount":176,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":136066177,"gmtCreate":1621986253299,"gmtModify":1634185031474,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Buy the dip","listText":"Buy the dip","text":"Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/136066177","repostId":"1104962084","repostType":4,"repost":{"id":"1104962084","kind":"news","pubTimestamp":1621985755,"share":"https://www.laohu8.com/m/news/1104962084?lang=&edition=full","pubTime":"2021-05-26 07:35","market":"us","language":"en","title":"Cramer says keep buying dips in the stock market due to 'stampede' of bullish catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=1104962084","media":"cnbc","summary":"KEY POINTS\n\nInvestors should be looking to buy any pullbacks in the stock market, \"Mad Money\" host J","content":"<div>\n<p>KEY POINTS\n\nInvestors should be looking to buy any pullbacks in the stock market, \"Mad Money\" host Jim Cramer said Tuesday.\n\"The stock market runs on cycles. When you have this many running at once, ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/why-jim-cramer-says-to-keep-buying-dips-in-the-stock-market.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cramer says keep buying dips in the stock market due to 'stampede' of bullish catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCramer says keep buying dips in the stock market due to 'stampede' of bullish catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-26 07:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/05/25/why-jim-cramer-says-to-keep-buying-dips-in-the-stock-market.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nInvestors should be looking to buy any pullbacks in the stock market, \"Mad Money\" host Jim Cramer said Tuesday.\n\"The stock market runs on cycles. When you have this many running at once, ...</p>\n\n<a href=\"https://www.cnbc.com/2021/05/25/why-jim-cramer-says-to-keep-buying-dips-in-the-stock-market.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯","SPY":"标普500ETF",".SPX":"S&P 500 Index"},"source_url":"https://www.cnbc.com/2021/05/25/why-jim-cramer-says-to-keep-buying-dips-in-the-stock-market.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1104962084","content_text":"KEY POINTS\n\nInvestors should be looking to buy any pullbacks in the stock market, \"Mad Money\" host Jim Cramer said Tuesday.\n\"The stock market runs on cycles. When you have this many running at once, the averages tend to be pretty resilient,\" Cramer said.\n\nInvestors should take advantage of market pullbacks in the near-term, CNBC'sJim Cramersaid Tuesday, suggesting there's a range of positive catalysts that will propel stocks higher.\n\"The stock market runs on cycles. When you have this many running at once, the averages tend to be pretty darn resilient,\" the\"Mad Money\"host said, shortly after theS&P 500andDow Jones Industrial Averagebothclosed lower by 0.2%. \"That's why I think you need to keep buying the dips. There's just too much to like.\"\nWhile he said the Federal Reserve will eventually adjust its highly accommodative monetary policy, Cramer contended there is a \"stampede of smaller bull cases\" to support the market untilcentral bank action is a more imminent threat.\nChief among them is the robust reopening of the economy this summer as Covid vaccinations allow for more activity, Cramer said. In addition to seeing more upside in cruise and casino stocks, Cramer expressed optimism around theme-park operators such asDisneyandCedar Fair.\nMall operators likeSimon Property Groupand their tenants such asL BrandsandGaphave also bounced back stronger than most expected, Cramer said.\nThe booming economy also is lifting cyclical stocks from those in agriculture such asDeereto steel makersNucor,Cleveland-CliffsandUnited States Steel Corporation,according to Cramer. He added that the housing cycle still appears to be strong, benefiting stocks in the space such asLennar.\n\"Then there's the health insurance bull market,\" Cramer said, pointing toUnitedHealth,Centene,Cigna,Humanaand Aetna-parentCVS. \"They are simply saying welcome aboard. They can be bought on any rare dip.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":197,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":197640942,"gmtCreate":1621466292186,"gmtModify":1634189022066,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Good to know pls like and comment","listText":"Good to know pls like and comment","text":"Good to know pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/197640942","repostId":"1126891253","repostType":4,"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194655324,"gmtCreate":1621379748668,"gmtModify":1634192089088,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Pls like and comment","listText":"Pls like and comment","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/194655324","repostId":"2136995492","repostType":4,"isVote":1,"tweetType":1,"viewCount":162,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":608814331,"gmtCreate":1638678672076,"gmtModify":1638678722248,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/608814331","repostId":"2188787815","repostType":4,"isVote":1,"tweetType":1,"viewCount":384,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":878663441,"gmtCreate":1637190745251,"gmtModify":1637190745748,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Oh well","listText":"Oh well","text":"Oh well","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/878663441","repostId":"2184510828","repostType":4,"isVote":1,"tweetType":1,"viewCount":307,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":840870795,"gmtCreate":1635638773016,"gmtModify":1635638773147,"author":{"id":"3575234837042918","authorId":"3575234837042918","name":"Rbj","avatar":"https://static.tigerbbs.com/363acddaa9c1e92690a16e7dd67b6484","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575234837042918","authorIdStr":"3575234837042918"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/840870795","repostId":"2179223688","repostType":4,"isVote":1,"tweetType":1,"viewCount":215,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}